ADME studies and preliminary safety pharmacology of LDT5, a lead compound for the treatment of benign prostatic hyperplasia

This study aimed to estimate the absorption, distribution, metabolism and excretion (ADME) properties and safety of LDT5, a lead compound for oral treatment of benign prostatic hyperplasia that has previously been characterized as a multi-target antagonist of α(1A)-, α(1D)-adrenoceptors and 5-HT(1A)...

Descripción completa

Detalles Bibliográficos
Autores principales: Noël, F., Nascimento-Viana, J.B., Romeiro, L.A.S., Silva, R.O., Lemes, L.F.N., Oliveira, A.S., Giorno, T.B.S., Fernandes, P.D., Silva, C.L.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Divulgação Científica 2016
Materias:
Biomedical Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5188857/
https://www.ncbi.nlm.nih.gov/pubmed/27901175
http://dx.doi.org/10.1590/1414-431X20165542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5188857/
https://www.ncbi.nlm.nih.gov/pubmed/27901175
http://dx.doi.org/10.1590/1414-431X20165542

Ejemplares similares